Changing temperature management for cardiopulmonary bypass

Practical conduct of open heart procedures for congenital heart lesions

Open heart surgery on infants with congenital heart lesions can be challenging not only in terms of the surgical procedure itself but also for setting up ideal conditions for safe and smooth conduct of cardiopulmonary bypass (CPB). The surgeon has to deal with a variety of lesions in a subgroup of patients who offer little room for any error. Familiarity with the principles of CPB, check lists and protocols go a long way in improving outcome in this critical group of patients.

Pharmacologic options for reducing the shivering response to therapeutic hypothermia

Recent literature has demonstrated significant improvements in neurologic outcomes in patients who have received induced hypothermia in the setting of out-of-hospital cardiac arrest. Through multiple metabolic mechanisms, the induction of hypothermia slows the progression and devastation of transient cerebral hypoxia. Despite these benefits, the desired reduction in core temperature is often a challenging venture as the body attempts to maintain homeostasis through the induction of thermoregulatory processes aimed at elevating body temperature. Shivering is an involuntary muscular activity that enhances heat production in an attempt to restore homeostasis. For successful induction and maintenance of induced hypothermia, shivering, as well as other thermoregulatory responses, must be overcome. Several pharmacologic options are available, either used alone or in combination, that safely and effectively prevent or treat shivering after the induction of hypothermia. We conducted a PubMed search (1966-March 2009) to identify all human investigations published in English that discussed pharmacologic mechanisms for the control of shivering. Among these options, clonidine, dexmedetomidine, and meperidine have demonstrated the greatest and most clinically relevant impact on depression of the shivering threshold. More research in this area is needed, however, and the role of the clinical pharmacist in the development and implementation of this therapy needs to be defined.

Cerebral dysfunction after cardiac surgery--are we moving forward?

This review focuses on the effects of cardiac surgery and cardiopulmonary bypass on the brain, with special emphasis on the results of recently conducted studies. The incidence of postoperative neurological and neuropsychological deficits and risk factors for cerebral injury are reviewed. The relationships between cerebral embolic load, release of biochemical markers of brain injury and cognitive dysfunction after cardiac surgery are also reviewed. Finally, recently gained information on the management of cardiopulmonary bypass is discussed, along with the results of recent pharmacological neuroprotective trials in patients undergoing cardiac surgery.

Acute kidney injury associated with cardiac surgery

Acute renal failure (ARF) occurs in up to 30% of patients who undergo cardiac surgery, with dialysis being required in approximately 1% of all patients. The development of ARF is associated with substantial morbidity and mortality independent of all other factors. The pathogenesis of ARF involves multiple pathways. Hemodynamic, inflammatory, and nephrotoxic factors are involved and overlap each other in leading to kidney injury. Clinical studies have identified risk factors for ARF that can be used to determine effectively the risk for ARF in patients who undergo bypass surgery. These high-risk patients then can be targeted for renal protective strategies. Thus far, no single strategy has demonstrated conclusively its ability to prevent renal injury after bypass surgery. Several compounds such as atrial natriuretic peptide and N-acetylcysteine have shown promise, but large-scale trials are needed.

Cardiopulmonary bypass temperature and brain function

A debate has emerged in recently published studies about the optimum cardiopulmonary bypass temperature for good neurological outcome - warm vs. cold, i.e. normothermic vs. hypothermic. Although many comparative studies have been performed, the results of these studies are inconclusive and are difficult to interpret. Brain function has been studied in terms of neurological and neuropsychological outcome, protein S100beta levels as a marker of brain damage, and cerebral oxygenation using jugular bulb oximetry and near-infrared spectroscopy. The studies produce no conclusive proof of the superiority of warm or cold cardiopulmonary bypass. However, it appears that any degree of bypass hypothermia (< 35 degrees C) may protect the brain. On the other hand, even a slight increase in bypass temperature to > 37 degrees C may cause marked brain injury.